The evaluation of the oxidative stress parameters in patients with primary angle-closure glaucoma

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Chang, Dong ^a   Sha, Qian ^a   Zhang, Xuefei ^a   Liu, Peipei ^a   Rong, Shengzhong ^a   Han, Tao ^a   Liu, Ping ^a   Pan, Hongzhi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ADVANCED OXIDATION PROTEIN PRODUCT; ALKADIENE; CARBONYL DERIVATIVE; CHOLESTEROL; CONJUGATED DIENE; ISCHEMIA MODIFIED ALBUMIN; MALONALDEHYDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 4-HYDROXY-2-NONENAL; 8 OXO 7,8 DIHYDRODEOXYGUANINE; 8-OXO-7,8-DIHYDRODEOXYGUANINE; ALDEHYDE; BIOLOGICAL MARKER; DRUG DERIVATIVE; GUANINE; ISCHEMIA-MODIFIED ALBUMIN; SERUM ALBUMIN;

ADULT; ARTICLE; CLOSED ANGLE GLAUCOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEGRADATION KINETICS; DISEASE ASSOCIATION; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIMARY GLAUCOMA; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UPREGULATION; AGED; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTEIN CARBONYLATION; RISK FACTOR;

AGED; ALDEHYDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLAUCOMA, ANGLE-CLOSURE; GUANINE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RISK FACTORS; SERUM ALBUMIN;

EID: 80855134302     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027218     Document Type: Article

References (49)

1. Izzotti A, Bagnis A, Saccà SC, (2006) The role of oxidative stress in glaucoma. Mutat Res 612: 105-14.
2. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF, (2004) Oxidative stress markers in aqueous humor of glaucoma patients. Am J Ophthalmol 137: 62-9.
3. Tezel G, (2006) Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res 25: 490-513.
4. Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A, (2005) Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol 123: 458-63.
5. Feilchenfeld Z, Yücel YH, Gupta N, (2008) Oxidative injury to blood vessels and glia of the pre-laminar optic nerve head in human glaucoma. Exp Eye Res 87: 409-14.
6. Kumar DM, Agarwal N, (2007) Oxidative stress in glaucoma: a burden of evidence. J Glaucoma 16: 334-43.
7. Wiggs JL, (2007) Genetic etiologies of glaucoma. Arch Ophthalmol 125: 30-7.
8. Grieshaber MC, Flammer J, (2005) Blood flow in glaucoma. Curr Opin Ophthalmol 16: 79-83.
9. Harju M, Vesti E, (2001) Blood flow of the optic nerve head and peripapillary retina in exfoliation syndrome with unilateral glaucoma or ocular hypertension. Graefes Arch Clin Exp Ophthalmol 239: 271-7.
10. Abu-Amero KK, Morales J, Bosley TM, (2006) Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 47: 2533-41.
11. Saccà SC, Izzotti A, Rossi P, Traverso C, (2007) Glaucomatous outflow pathway and oxidative stress. Exp Eye Res 84: 389-99.
12. Mozaffarieh M, Grieshaber MC, Flammer J, (2008) Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis 14: 224-33.
13. Gherghel D, Griffiths HR, Hilton EJ, Cunliffe IA, Hosking SL, (2005) Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 46: 877-83.
14. Quigley HA, Broman AT, (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90: 262-7.
15. Quigley HA, (1996) 1993 Open-angle glaucoma. N Engl J Med 328: 1097-1106.
16. Sarfarazi M, (1997) Recent advances in molecular genetics of glaucomas. Hum Mol Genet 6: 1667-1677.
17. Izzotti A, Saccà SC, Cartiglia C, De Flora S, (2003) Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. Am J Med 114: 638-46.
18. Vinson JA, (2006) Oxidative stress in cataracts. Pathophysiology 13: 151-162.
19. Lin J, Tanaka Y, Arai K, (1998) Copper ions and peroxidative reactions in the vitreous bodies of patients with diabetic retinopathy. Focus Diabetic Retinopathy 5: 55-59.
20. Tezel G, Yang X, Cai J, (2005) Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 46: 3177-87.
21. Poli G, Leonarduzzi G, Biasi F, Chiarpotto E, (2004) Oxidative stress and cell signalling. Curr Med Chem 11: 1163-1182.
22. Babizhayev MA, Bunin AY, (1989) Lipid peroxidation in open-angle glaucoma. Acta Ophthalmol (Copenh) 67: 371-377.
23. Bunin AIa, Babizhaev MA, Suprun AV, (1985) Participation of the lipid Peroxidation process in the destruction of the drainage system of the eye in open-angle glaucoma. Vestn Oftalmol 101: 13-6.
24. Ko ML, Peng PH, Ma MC, Ritch R, Chen CF, (2005) Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med 39: 365-73.
25. Yucel I, Akar Y, Yucel G, Ciftçioǧlu MA, Keleş N, et al. (2005) Effect of hypercholesterolemia on inducible nitric oxide synthase expression in a rat model of elevated intraocular pressure. Vision Res 45: 1107-14.
26. Alderman CJ, Shah S, Foreman JC, Chain BM, Katz DR, (2002) The role of advanced oxidation protein products in regulation of dendritic cell function. Free Radic Biol Med 32: 377-85.
27. de Zwart LL, Meerman JH, Commandeur JN, Vermeulen NP, (1999) Biomarkers of free radical damage: applications in experimental animals and in humans. Free Radic Biol Med 26: 202-26.
28. Kalousová M, Skrha J, Zima T, (2002) Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51: 597-604.
29. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, et al. (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-32.
30. Stadtman ER, Oliver CN, (1991) Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem 266: 2005-8.
31. Yaǧci R, Gürel A, Ersöz I, Keskin UC, Hepşen IF, et al. (2006) Oxidative stress and protein oxidation in pseudoexfoliation syndrome. Curr Eye Res 31: 1029-32.
32. Yan DB, Coloma FM, Metheetrairut A, Trope GE, Heathcote JG, et al. (1994) Deformation of the lamina cribrosa by elevated intraocular pressure. Br J Ophthalmol 78: 643-8.
33. Cho DK, Choi JO, Kim SH, Choi J, Rhee I, et al. (2007) Ischemia-modified albumin is a highly sensitive serum marker of transient myocardial ischemia induced by coronary vasospasm. Coron Artery Dis 18: 83-7.
34. Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB, (2005) Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 123: 140-5.
35. Kang SY, Suh JT, Lee W, (2005) Clinical usefulness of ischemia modified albumin in acute coronary syndrome. Korean J Lab Med 25: 306-311.
36. Lippi G, Montagnana M, Guidi GC, (2006) Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia. Int J Cardiol 108: 410-1.
37. Montagnana M, Lippi G, Volpe A, Salvagno GL, Biasi D, et al. (2006) Evaluation of cardiac laboratory markers in patients with systemic sclerosis. Clin Biochem 39: 913-7.
38. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, et al. (2004) Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 50: 1656-60.
39. Piwowar A, Knapik-Kordecka M, Warwas M, (2008) Ischemia-modified albumin level in type 2 diabetes mellitus- Preliminary report. Dis Markers 24: 311-7.
40. Gunduz A, Turedi S, Mentese A, Altunayoglu V, Turan I, et al. (2008) Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 26: 874-8.
41. Gunduz A, Turkmen S, Turedi S, Mentese A, Yulug E, et al. (2009) Time-dependent variations in ischemia-modified albumin levels in mesenteric ischemia. Acad Emerg Med 16: 539-43.
42. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC, (2004) Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 21: 29-34.
43. Roy D, Quiles J, Sinha M, Aldama G, Gaze D, et al. (2004) Effect of direct-current cardioversion on ischemiamodified albumin levels in patients with atrial fibrillation. Am J Cardiol 93: 366-8.
44. Gunduz A, Turedi S, Mentese A, Karahan SC, Hos G, et al. (2008) Ischemia modified albumin in the diagnosis of acute mesenteric ischemia: a preliminary study. Am J Emerg Med 26: 202-5.
45. Mitsudo S, Brandt LJ, (1992) Pathology of intestinal ischemia. Surg Clin North Am 72: 43-63.
46. Ward PA, Till GO, Hatherill JR, Annesley TM, Kunkel RG, (1985) Systemic complement activation, lung injury, and products of lipid peroxidation. J Clin Invest 76: 517-27.
47. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, et al. (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-13.
48. Reznick AZ, Packer L, (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233: 357-63.
49. Bar-Or D, Lau E, Winkler JV, (2000) A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia preliminary report. J Emerg Med 19: 311-5.